Phathom Pharmaceuticals Inc
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
PHAT$5.33+1.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(in thousands)
| Nine Months EndedSeptember 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities | ||
| Net loss | $(259,875) | $(122,022) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 602 | 390 |
| Stock-based compensation | 17,360 | 20,441 |
| Issuance of PIK interest debt | 2,724 | 2,684 |
| Accrued interest on revenue interest financing liability | 35,656 | 16,265 |
| Amortization of debt discount | 1,563 | 1,311 |
| Inventory reserve | 716 | — |
| Other | 4,202 | 1,468 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (1,784) | (7,813) |
| Accounts receivable, net | (19,415) | — |
| Accounts payable and accrued expenses | 14,993 | (3,857) |
| Accrued clinical trial expenses | — | 661 |
| Accrued interest | 376 | 103 |
| Operating right-of-use assets and lease liabilities | 134 | 147 |
| Inventory | (566) | (111) |
| Other long-term assets | — | (3,450) |
| Net cash used in operating activities | (203,314) | (93,783) |
| Cash flows from investing activities | ||
| Cash paid for property and equipment | (130) | (1,159) |
| Net cash used in investing activities | (130) | (1,159) |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock from exercise of stock options | 303 | 124 |
| Net proceeds from issuance of debt | 34,650 | — |
| Net proceeds from underwritten public offering | 121,775 | 141,390 |
| Net proceeds from issuance of common stock under ATM facility | — | 14,073 |
| Net cash provided by financing activities | 156,728 | 155,587 |
| Net (decrease) increase in cash and cash equivalents and restricted cash | (46,716) | 60,645 |
| Cash and cash equivalents and restricted cash – beginning of period | 384,256 | 155,890 |
| Cash and cash equivalents and restricted cash – end of period | $337,540 | $216,535 |
| Supplemental disclosure of cash flow information | ||
| Interest paid | $12,478 | $8,222 |
| Supplemental disclosure of noncash investing and financing activities: | ||
| Final interest payment fee | $1,050 | $— |
| Settlement of ESPP liability in common stock | $2,401 | $1,417 |
| Settlement of 401(k) liability in common stock | $3,683 | $1,612 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.